AXL and lung carcinoma: Recent studies report that the blockade of TGF-β/TβR, Wnt/β-catenin, and AXL/Gas6 signaling can potentially reduce the EGFR-TKI resistance in lung cancer A549, HCC827, and PC9 cell lines [3,4,11].